The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Not sure if paying off debt first would be more beneficial, before paying dividends
A move to the main market could be beneficial to the share price, would then appear on the radar of more investment fund managers.
There is more stuff they are working on, for example: They are looking at developing a female version of eroxon! Aparently it can make the clitarus arowsed/erect.
Yes, spreadex are hedging against the difference between their positive and negative open positions, as/when they close, the equivalent shares will be sold. Have seen it before, a few years ago, someone took a big spreadex bet on an AIM stock, they lost out, think it was Alba minerals, but not so sure now.
VLG is no stranger to M&A, been there done that, hopefully if/when it will be another good one
This looks very lucrative
Starting from 2024, a new revenue segment called Private label will be introduced to the Group, referring to products manufactured by VLG-owned factories, which develop formulations for retailers, who will sell these products through their own retail channels. This is aimed at providing a more comprehensive understanding of our business performance by segregating these revenues from the currently reported segments. As revenue from this segment grows, the Group will consider reporting and disclosing performance separately in future periods.
Customer Brands refers to products manufactured by VLG-owned factories, which co-develop formulations with customers, who will distribute and market these products under their own brand names
Debt reduced further in 2024
Group net leverage7 reduction to 1.30x (2022: 1.65x).
Group net leverage7 reduced further to 1.15x at 31 March 2024
Dug, for sure, insider trading is a thing that goes on, and in my opinion, it's rife on AIM, the big trick though is proving it! All private investors have got to go on is suspicion flagged up by coincidence, how many times do you see an increase in volume and share price just before good news is announced! The situation here though, Diggle sold shares before the poor trading update was announced, so was that just a lucky coincidence, or was someone in the know, investors will need to make their own mind up on that play, as for proof, no one on the outside will have any.
Apart from treating private investors with contempt, they must also think we are stupid and unable to remember what was said. "Word of mouth was going to sell CiRT" Because medical professionals have heard it all before from sales people.
@ DugWalker, "one critical sales person took leave of absence" yes Dug, that's basically what they said, LOL, I'm not buying that explanation though, It just doesn't make sense to me, an oncologist who has used the test and is happy with the results will not need to be enticed by a salesperson to buy again, he/her would repete buy because it was useful, also by recommendation, enlighten other about the test in their field. The company said, word of mouth was going to sell the product! So with one sales guy out, you would expect a bit of a slowdown in growth, or at worse, sales to be flat until he is back, but a declin, that's something else.
I agree Dug, the transform trial is a massive validation trial for the PSE test, OBD should at least offer the test at cost price, or are they worried about the claimed 94% accuracy might not stand up to scrutiny!